14.02.2017
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG: Formycon Plans Change in New SME Stock Exchange Segment 'Scale'
DGAP-News: Formycon AG / Key word(s): IPO/Letter of Intent
Formycon AG: Formycon Plans Change in New SME Stock Exchange Segment 'Scale'
14.02.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release // February 14, 2017
Formycon Plans Change in New SME Stock Exchange Segment "Scale"
- Biosimilar developer requests inclusion for the launch of the segment
on March 1, 2017
- Formycon will continue to provide transparent and comprehensive
financial market communications in future
Munich - The biosimilar company Formycon plans, with effect from March 1,
2017, to switch to Deutsche Börse AG's new stock exchange segment "Scale"
for small and medium-sized enterprises (SMEs). A corresponding request for
inclusion in the SME segment has been lodged with Deutsche Börse AG.
Formycon will be accompanied by its capital market partner Süddeutsche
Aktienbank.
The new segment, which will be more strictly regulated in some areas both
in terms of its inclusion and its follow-up requirements than the entry
standard, will improve access to investors for small and medium-sized
companies and place the emphasis on transparency and quality criteria.
Deutsche Börse is therefore supporting the goals of the German government
of sustaining innovation and growth in Germany and is keen, through this
action, to make a contribution towards Germany's sustainability as a
business location.
"We welcome the new segment, and we anticipate further attention from
investors and analysts as a result", says Dr. Nicolas Combé, Chief
Financial Officer at Formycon. "We also believe that the new SME segment
represents a sensible further development of the entry standard. It should
lead to more transparency on the market and could evolve into an indicator
for small and medium-sized quality companies."
Formycon shares have been listed in the curb segment entry standard since
2012. Formycon has already reported beyond the specified minimum standards
that are imposed on corporate publicity in the past. The company
communicates quarterly in German and English, for example, on the progress
of its business and regularly updates investors and analysts. Formycon will
continue to do so in the future.
Formycon develops follow-on versions of biopharmaceuticals, so-called
biosimilars. Currently the company is working on four biosimilar projects,
which are in different stages of pre-clinical and clinical development. Two
of them have already been out-licensed.
About Formycon:
Formycon is a leading independent pure play developer of biosimilars and
has become a recognized innovator in this field. The company has extensive
experience in the development of complex biological molecules. Formycon's
specialist expertise allows the company to develop high-quality biosimilars
that meet the strict regulatory requirements of highly regulated markets
such as Europe and the United States. Formycon currently has four
biosimilars under development, of which two have been licensed out.
About biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have
revolutionized the treatment of serious diseases such as cancer, diabetes,
rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming
years, many of these biotech drugs will lose their patent protection - and
by 2020, medications with revenues of more than USD 100 billion will be off
patent. Biosimilars are follow-on versions of biopharmaceuticals, for which
exclusivity has expired. They are approved via stringent regulatory
pathways in highly regulated markets (such as EU, US, Japan, Canada,
Australia) based on proven similarity of the biosimilar with the originator
biopharmaceutical reference product. While the global market for
biosimilars is currently more than USD 3.0 billion, industry experts expect
this figure to grow tenfold by the year 2025. In contrast to traditional
generic drugs, the development and production of biosimilars is highly
complex and requires specialized expertise.
Contact:
Thorsten Schüller
Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
phone +49 (0) 89 - 86 46 67 150
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This press release may contain forward-looking statements and information
which are based on our current expectations and certain assumptions.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, performance of the company, development of the products and the
estimates given here.
Such known and unknown risks and uncertainties comprise, among others, the
research and development, the regulatory approval process, the timing of
the actions of regulatory bodies and other governmental authorities,
clinical results, changes in laws and regulations, product quality, patient
safety, patent litigation, contractual risks and dependencies from third
parties. With respect to pipeline products, Formycon AG does not provide
any representation, warranties or any other guarantees that the products
will receive the necessary regulatory approvals or that they will prove to
be commercially exploitable and/or successful.
Formycon AG assumes no obligation to update these forward-looking
statements or to correct them in case of developments which differ from
those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an
offer to buy or subscribe for securities of Formycon AG. No public offering
of securities of Formycon AG will be made nor is a public offering
intended.
This document and the information contained therein may not be distributed
in or into the United States of America, Canada, Australia, Japan or any
other jurisdictions, in which such offer or such solicitation would be
prohibited. This document does not constitute an offer for the sale of
securities in the United States.
---------------------------------------------------------------------------
14.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Regulated Unofficial Market in Berlin, Tradegate Exchange;
Open Market (Entry Standard) in Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
544091 14.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB